EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Versatile lipoparticles for the co-delivery of TLR3 and TLR7/8 ligands as vaccine adjuvants: in vitro and in vivo evaluations

Valentine Ginet, Cynthia Garapon, Céline Coiffier, Jean-Paul Salvi, Camille Ayad, Sophia Djebali, Stéphane Paul, Jérôme Sohier, Pierre-Olivier Vidalain, Bernard Verrier

Journal of Controlled Release · 2026

DOI: 10.1016/j.jconrel.2026.115271 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Controlled Release, 2026. Verfasst von Valentine Ginet und 9 weiteren Autor:innen. Beteiligte Einrichtung: Laboratoire de Biologie Tissulaire et Ingénierie Thérapeutique, Institut de Biologie et Chimie des Protéines, UMR 5305 CNRS/Université Claude Bernard…. Hauptthemen laut MEDLINE: Toll-Like Receptor 8, Toll-Like Receptor 3, Toll-Like Receptor 7, Nanoparticles. Die Arbeit nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: French National Cancer Institute, Ministère de l'Enseignement supérieur de la Recherche et de l'Innovation, French National Research Agency.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recent subunit vaccines based on purified protein antigens have shown reduced immunogenicity and efficacy, highlighting the need for adjuvants to improve the level and quality of the induced immune responses. Toll-like receptors (TLR) are innate immunity receptors that represent promising targets for the development of agonist-based vaccine adjuvants. Combinations of TLR ligands represent an attractive strategy for developing better adjuvants, but remain underexplored due to technical difficulties related to the co-delivery of molecules with distinct physicochemical properties. In this study, we designed LipoParticles based on a polylactic acid (PLA) core with a lipid envelope to co-deliver 3M052, a small molecule agonist of TLR7/8, and Poly (I:C), a synthetic dsRNA that activates TLR3. In vitro, the coordinated activation of the two TLR pathways by these LipoParticles was found more effective than single agonists in stimulating bone marrow-derived macrophages (BMDMs), as evidenced by the increased secretion of several cytokines, such as IL-12p70, TNF-α and IL-1β, and the induction of complementary clusters of immunity gene. Cytokine profiling and transcriptomic analysis also showed that the co-stimulation of TLR3 and TLR7/8 specifically induced inhibitory factors, such as IL-10, IL-19 and IRAK-M. Importantly, following in vivo immunization of mice, the dual formulation appears to modulate the immune profile, with an improved Th1 polarization assessed by quantifying type II IFN secreted by splenocytes, which is a promising finding for vaccine development. Overall, our results validate the efficacy of our LipoParticles as a delivery platform for combinations of TLR ligands. This new carrier will be useful for testing combinations of adjuvant molecules and for selecting those capable of boosting antigen-specific immunity, as this appears to be more complex to achieve than anticipated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Toll-Like Receptor 8Toll-Like Receptor 3Toll-Like Receptor 7NanoparticlesAdjuvants, VaccinePoly I-CAdjuvants, ImmunologicMembrane GlycoproteinsAnimalsMice, Inbred C57BLLigandsToll-Like Receptor AgonistsMacrophagesCytokinesFemalePolyestersMiceProtein Subunit Vaccines

Stichwörter der Autor:innen

Hybrid nanoparticlesLipoparticlesPolylactic acidToll-like receptor ligandsVaccine adjuvants

Substanzen

Toll-Like Receptor 8Toll-Like Receptor 3TLR3 protein, mouseLigandsToll-Like Receptor 7Toll-Like Receptor AgonistsTLR8 protein, mouseAdjuvants, VaccinePoly I-Cpoly(lactide)

Autor:innen und Institutionen

  • Laboratoire de Biologie Tissulaire et Ingénierie Thérapeutique, Institut de Biologie et Chimie des Protéines, UMR 5305 CNRS/Université Claude Bernard Lyon 1, Lyon, France; Adjuvatis, Bâtiment Laennec, 60 Av. Rockefeller…
  • Laboratoire de Biologie Tissulaire et Ingénierie Thérapeutique, Institut de Biologie et Chimie des Protéines, UMR 5305 CNRS/Université Claude Bernard Lyon 1, Lyon, France.
  • Adjuvatis, Bâtiment Laennec, 60 Av. Rockefeller, 69008 Lyon, France.
  • Centre International de Recherche en Infectiologie, INSERM U1111, CNRS UMR 5308, Université Claude Bernard Lyon 1, Ecole Normale Supérieure de Lyon, Lyon, France.
  • Team GIMAP, Centre International de Recherche en Infectiologie, INSERM U1111, CNRS UMR 5308, Université Claude Bernard Lyon 1, Ecole Normale Supérieure de Lyon, Lyon, France.
  • Team VIRIMI, Centre International de Recherche en Infectiologie, INSERM U1111, CNRS UMR 5308, Université Claude Bernard Lyon 1, Ecole Normale Supérieure de Lyon, Lyon, France. Electronic address: pierre-olivier.vidalain…

Förderung

  • French National Cancer Institute
  • Ministère de l'Enseignement supérieur de la Recherche et de l'Innovation
  • French National Research Agency

Zitieren

APA

Ginet, V., Garapon, C., Coiffier, C., Salvi, J. P., Ayad, C., Djebali, S., Paul, S., Sohier, J., Vidalain, P. O., & Verrier, B. (2026). Versatile lipoparticles for the co-delivery of TLR3 and TLR7/8 ligands as vaccine adjuvants: in vitro and in vivo evaluations. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2026.115271

Vancouver

Ginet V, Garapon C, Coiffier C, Salvi JP, Ayad C, Djebali S, et al. Versatile lipoparticles for the co-delivery of TLR3 and TLR7/8 ligands as vaccine adjuvants: in vitro and in vivo evaluations. Journal of Controlled Release. 2026. doi:10.1016/j.jconrel.2026.115271

BibTeX
@article{Ginet2026,
  author = {Ginet, Valentine and Garapon, Cynthia and Coiffier, Céline and Salvi, Jean-Paul and Ayad, Camille and Djebali, Sophia and Paul, Stéphane and Sohier, Jérôme and Vidalain, Pierre-Olivier and Verrier, Bernard},
  title = {Versatile lipoparticles for the co-delivery of TLR3 and TLR7/8 ligands as vaccine adjuvants: in vitro and in vivo evaluations},
  journal = {Journal of Controlled Release},
  year = {2026},
  doi = {10.1016/j.jconrel.2026.115271}
}
Kostenlos starten →